BOSTON, Jan. 6, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, February 7, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 7, 2023.
The call can be accessed via teleconference at: Q3 2023 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/m6/p/qyrbnnof https://edge.media-server.com/mmc/p/pt8ugsbv
A replay of the conference call and webcast will be available for one year beginning on February 7, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contact:
Olga Guyette, Sr. Director, Investor Relations & Treasury
(781) 356-9763
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Josh Gitelson, Director, Global Communications
(781) 356-9776
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$89.22 |
| Daily Change: | -1.53 -1.69 |
| Daily Volume: | 454,955 |
| Market Cap: | US$4.570B |
August 15, 2024 August 08, 2024 July 30, 2024 June 18, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
